Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
Launched by MERCK SHARP & DOHME LLC · Aug 30, 2001
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
In this open-label, nonrandomized study, 120 HIV-infected patients are stratified into two groups: failed nelfinavir vs protease inhibitor-naive. All patients receive indinavir plus efavirenz plus adefovir dipivoxil plus and L-carnitine, orally. Plasma vRNA is measured every 4 weeks until Week 16, then every 8 weeks for the remainder of the 48-week study.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • Serologically documented HIV infection.
- • Baseline CD4 count greater than or equal to 50 cells and vRNA greater than or equal to 10,000 copies/ml.
- • Parental consent for patients under 18.
- Nelfinavir-Failure Group:
- • Must have protease inhibitor experience solely with nelfinavir and be considered drug-adherent.
- • Must be candidate for changing therapy because of virologic failure and be receiving nelfinavir at entry (at least 16 weeks of nelfinavir plus NRTI therapy with at least a 10-fold decline in vRNA due to nelfinavir therapy and a subsequent increase toward the patient's baseline vRNA of at least 10-fold).
- Control Group:
- • Must have received any combination of currently licensed nucleoside reverse transcriptase inhibitors for at least 16 weeks.
- • Must be naive to efavirenz, adefovir dipivoxil, and other NRTI's.
- • Exclusion Criteria
- Prior Medication:
- Excluded:
- Control group:
- • Prior efavirenz, adefovir dipivoxil, or other non-nucleoside reverse transcriptase inhibitors.
- Required:
- Nelfinavir-failure patients:
- • At least 16 weeks of nelfinavir.
- Control group:
- • At least 16 weeks of any combination of currently licensed nucleoside reverse transcriptase inhibitors.
About Merck Sharp & Dohme Llc
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines that address unmet medical needs. With a strong focus on research and development, Merck Sharp & Dohme leverages advanced science and technology to enhance patient outcomes across various therapeutic areas, including oncology, infectious diseases, and cardiovascular health. Committed to ethical practices and regulatory compliance, the company actively engages in clinical trials to advance medical knowledge and improve health care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Los Angeles, California, United States
New Haven, Connecticut, United States
Wilmington, Delaware, United States
Honolulu, Hawaii, United States
Chicago, Illinois, United States
New York, New York, United States
Stonybrook, New York, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials